Ulcerative Colitis Pipeline H1 2017 provides Ulcerative Colitis therapeutics development pipeline of 85 Companies. Report provides all Ulcerative Colitis - Dormant Projects and Discontinued Products and Number of Products under Development for Ulcerative Colitis,
Ulcerative Colitis Pipeline Review H1 2017 provides an overview of the Ulcerative Colitis therapeutics landscape. Ulcerative Colitis (Gastrointestinal) pipeline guide reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, and Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 14, 32, 25, 53, 9 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.
You can inquire for Complete Ulcerative Colitis Pipeline Review H1 2017 Report @ www.reportsnreports.com/contact…ame=992899
Companies Analysed Which Involved in Ulcerative Colitis Therapeutics Development 4D Pharma PLC, AbbVie Inc, AbGenomics International Inc, Abivax SA, Adello Biologics LLC, Advinus Therapeutics Ltd, Aerpio Therapeutics Inc, Akebia Therapeutics Inc, Allergan Plc, Am-Pharma BV, Amgen Inc, Aptevo Therapeutics Inc, Arena Pharmaceuticals Inc, Atlantic Bio Sci LLC, Atlantic Healthcare Plc, Blueberry Therapeutics Ltd, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, ChemoCentryx Inc, ChironWells GmbH, Circle33 LLC, Coherus BioSciences Inc, Cosmo Pharmaceuticals NV, Dr. August Wolff GmbH & Co KG Arzneimittle, Dr.
Falk Pharma GmbH, EA Pharma Co Ltd, Eli Lilly and Company, Enceladus Pharmaceuticals BV, Enterome Bioscience SA, Ferring International Center SA, Galapagos NV, Genentech Inc, Genor BioPharma Co Ltd, GlaxoSmithKline Plc, iCo Therapeutics Inc., Immune Therapeutics Inc, Inception Sciences Inc, InDex Pharmaceuticals AB, Innovate Biopharmaceuticals Inc, Intas Pharmaceuticals Ltd, Johnson & Johnson, Kaken Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, LG Chem, Ltd., LIPID THERAPEUTICS GmbH, Lycera Corp, Medestea Research & Production SpA, Merck & Co Inc, Merck KGaA, Miyarisan Pharmaceutical Company Ltd, Momenta Pharmaceuticals Inc, Morphotek Inc, Ogeda SA, Oncobiologics Inc, OSE Immunotherapeutics, Panacea Biotec Ltd, Pfizer Inc, Principia Biopharma Inc, Protab Ltd, Protagonist Therapeutics Inc, Protalix BioTherapeutics Inc, Qu Biologics Inc, Re-Pharm Ltd, Rebiotix Inc, Reliance Life Sciences Pvt Ltd, Rock Creek Pharmaceuticals, Inc., Sandoz International GmbH, Sareum Holdings Plc, Seres Therapeutics Inc, Shire Plc, Sigmoid Pharma Ltd, Stelic Institute & Co Inc, sterna biologicals Gmbh & Co KG, Synergy Pharmaceuticals Inc, Synlogic Inc, Takeda Pharmaceutical Company Ltd, Theravance Biopharma Inc, Thetis Pharmaceuticals LLC, Tillotts Pharma AG, TopiVert Ltd, Trino Therapeutics Ltd, UCB SA, Ventria Bioscience, Vivelix Pharmaceuticals Ltd
Ulcerative Colitis - Pipeline Review, H1 2017 Pharmaceutical and Healthcare latest pipeline guide provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Get this Research Report at www.reportsnreports.com/contact…ame=992899
Scope:
The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal) and pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources also covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. Ulcerative Colitis Pipeline Review H1 2017 features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities, reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects and evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.This Report encapsulates all the dormant and discontinued pipeline projects and reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Access this research report Direct from: www.reportsnreports.com/purchas…ame=992899
Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Major Table OF Content
- Global Markets Direct Report Coverage
- Ulcerative Colitis - Overview
- Ulcerative Colitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Ulcerative Colitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ulcerative Colitis - Companies Involved in Therapeutics Development
List of Tables
Number of Products under Development for Ulcerative Colitis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, H1 2017
Ulcerative Colitis - Pipeline by Biocon Ltd, H1 2017
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Ulcerative Colitis - Pipeline by Celgene Corp, H1 2017
Ulcerative Colitis - Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2017
Ulcerative Colitis - Pipeline by Incyte Corp, H1 2017
Ulcerative Colitis - Dormant Projects, H1 2017
News From
ReportsnReports Category: Industry Reports & Market Analysis Profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. Email us at This email address is being protected from spambots. You need JavaScript enabled to view it..
